Influenza hemagglutinin and neuraminidase variants

Details Influenza hemagglutinin and neuraminidase variants Influenza hemagglutinin and neuraminidase variants

2006-03-06

2008-12-02

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S239000, C434S186000, C434S199000, C434S209000

Reexamination Certificate

active

07459162

ABSTRACT:
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

REFERENCES:
patent: 3992522 (1976-11-01), Chanock et al.
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4634666 (1987-01-01), Engleman et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5690937 (1997-11-01), Parkin
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5820871 (1998-10-01), Palese et al.
patent: 5840520 (1998-11-01), Clarke et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5922326 (1999-07-01), Murphy
patent: 6033886 (2000-03-01), Conzelmann
patent: 6090391 (2000-07-01), Parkin
patent: 6146642 (2000-11-01), Garcia-Sastre
patent: 6146873 (2000-11-01), Kistner
patent: 6168943 (2001-01-01), Rose
patent: 7037707 (2006-05-01), Webster et al.
patent: 2002/0119445 (2002-08-01), Parkin
patent: 2002/0164770 (2002-11-01), Hoffmann
patent: 2003/0035814 (2003-02-01), Kawaoka
patent: 2003/0147916 (2003-08-01), Ferko
patent: 2004/0029251 (2004-02-01), Hoffman
patent: 2004/0137013 (2004-07-01), Katinger
patent: 2005/0042229 (2005-02-01), Yang
patent: 2005/0266026 (2005-12-01), Hoffmann
patent: 0 702 085 (1996-03-01), None
patent: 0 863 202 (1998-09-01), None
patent: 0 864 645 (1998-09-01), None
patent: 0 780 475 (1999-06-01), None
patent: 1826269 (2007-08-01), None
patent: WO-91-03552 (1991-03-01), None
patent: WO-93-21306 (1993-10-01), None
patent: WO-96-10632 (1996-04-01), None
patent: WO-96-34625 (1996-11-01), None
patent: WO-97-06270 (1997-02-01), None
patent: WO-97-12032 (1997-04-01), None
patent: WO-98-02530 (1998-01-01), None
patent: WO-98-13501 (1998-04-01), None
patent: WO-98-53078 (1998-11-01), None
patent: WO-99-02657 (1999-01-01), None
patent: WO-99-15672 (1999-04-01), None
patent: WO-00-53786 (2000-09-01), None
patent: WO-00-60050 (2000-10-01), None
MMWR of Mar. 4, 2005, Update-Infuenza Activity-United States 2004-2005 Season.
Daum et al, Influenza A (H3N2) Outbreak, Nepal, 2005, Emerging Infectious Diseases, vol. 11, No. 8, pp. 1186-1191.
Banerjee and Barik, 1992, “Gene expression of vesicular stomatitis virus genome RNA”, Virology. 188):417-28.
Baron and Barrett, 1997, “Rescue of Rinderpest Virus from Cloned cDNA”, J. Virol. 71:1265-1271.
Beare et al., 1975, “Trials in Man with Live Recombinants Made from A/PR/8/34 (H0 N1) and Wild H3 N2 Influenza Viruses”, Lancet 729-732.
Boyer et al., 1994, “Infectious transcripts and cDNA clones of RNA viruses”, Virology. 198:415-26.
Brigden and Elliott, 1996, “Rescue of a Segmented Negative-Strand RNA Virus Entirely from Cloned Complementary DNAS”, Proc. Natl. Acad. Sci. USA 93:15400-15404.
Buchholz et al., 1999 “Generation of Bovine Resp. Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture . . . ” J. Virol. 73:251-259.
Bukreyev et al., 1996, “Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene”, J Virol. 70(10):6634-41.
Castrucci et al., 1995, “Reverse genetics system. for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal M2..”, J Virol. 69(5):2725-28.
Chen et al., 1999, “Influenza A virus NS1 protein targets poly (A)-binding protein II of the cellular 3′-end processing machinery”, EMBO 18: 2273-2283.
Clarke et al., 2000, “Rescue of mumps virus from cDNAJ”, J Virol. 74 (10:4831-38.
Collins et al., 1991, “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations.”, Proc. Natl. Acad. Sci. USA 88:9663-9667.
Collins et al., 1995, “Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role . . . ” PNAS 92: 11563-1567.
Collins et al., 1996, “Parainfluenza Viruses”, Fields Virology, Lippincott-Raven Publishers, Phila., pp. 1205-1241.
Conzelmann, 1996, “Genetic manipulation of non-segmented negative-strand RNA viruses”, J Gen Virol. 77 (Pt 3):381-89.
Conzelmann et al., 1998, “Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes”, Annu Rev Genet. 32:123-62.
Conzelmann et al., 1996, “Genetic engineering of animal RNA viruses”Trends Microbiol. 4(10):386-93.
Conzelmann et al., 1994, “Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins”, J Virol. 68(2):713-19.
De la Luna et al., 1993, “Influenza virus naked RNA can be expressed upon transfection into cells co-expressing the three subunits . . . ” J. Gen. Virol. 74: 535-39.
De La Luna et al., 1995, “Influenza virus NS1 Protein Enhances the Rate of Translation Initiation of Viral mRNAs”, J. of Virol. 69: 2427-2433.
De and Banerjee, 1985, “Requirements and Functions of Vesicular Stomatitis Virus L and NS Proteins in the Transcription..”, Biochem. & Biophys. Res. Commun. 126:40-49.
De and Banerjee, 1993, “Rescue of synthetic analogs of genome RNA of human parainfluenza virus type 3”, Virology, 96:344-48.
De and Banerjee, 1994, “Reverse genetics of negative strand RNA viruses,” Indian J Biochem & Biophys. 31:367-76.
Dimock et al., 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermed. RNA of human parinfluenza virus type 3,”, J Virol. 67(5):2772-78.
Dreher et al., 1984, “Mutant Viral RNAs Synthesized in vitro Show Altered Aminoacylation and Replicase Template Activities”, Nature 311:171-175.
Dreher and Hall, 1988, “Mutational Analysis of the Sequence and Structural Requirements in Brome Mosaic Virus RNA for Minus Strand Promoter Activity”, J. Mol. Biol. 201:31-40.
Dunn et al., 1995, “Transcription of a recombinant bunyavirus RNA template by transiently expressed bunyavirus proteins”, Virology, 211:133-43.
Durbin et al., 1997, “Recovery of infectious Human Parainfluenza Virus Type 3 from cDNA”, Virol. 235:323-332.
Elliot et al., 1997, Abstract # 96 10.sup.th International conference on Negative Strand Viruses.
Elliott et al., 1991, “Some highlights of virus research in 1990”, J Gen Virol. 72:1761-79. Review.
Emerson and Yu, 1975, “Both NS and L Proteins are Required for in vitro RNA Synthesis by Vosicular Stomatitis Virus”, J. Virol. 15:1348-1356.
Enami and Palese, 1991, “High-Efficiency Formation of Influenza Virus Transfectants”, J. Virol. 65:2711-2713.
Enami et al., 1991, “An influenza virus containing nine different RNA segments”, Virology. 185:291-98.
Fahey and Schooley, 1992, “Status of Immune-Based Therapies in HIV Infection and AIDS”, Clin. Exp. Immunol. 88:1-5.
Fortes et al., 1994, “Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport”, EMBO J. 13: 704-712.
Garcia-Sastre A, Palese P, 1993. “Genetic manipulation of negative-strand RNA virus genomes”, Annu Rev Microbiol. 47:765-90.
Garcin et al., 1995, “A highly recombinogenic system for the recovery of infectious sendai paramyxovirus from cDNA: generation of a novel . . . ” EMBO J. 14: 6087-6094.
Goto et al.,1997, “Mutations Affecting the Sensitivity of the Influenza Virus Neuraminidase to 4-Guanidino-2,4-Dideoxy-2,3 Dehydro-N-Acetyineuraminic Acid”, Virol. 238:265-72.
Grosfeld et al., 1995, “RNA replication by respiratory syncytial virus (RSV) is directed by the N., P., and L proteins: transcription . . . ” J. Virol. 69(9):5677-86.
Hatada and Fukudo, 1992, “Binding of influenza A virus NS1 protein to dsRNA in vitro,” J. of Gen. Virol. 73: 3325-3329.
He et al., 1997, “Recovery of Infectious SV5 from Cloned DNA and Expression of a Foreign Gene”, Virol. 237:249-260.
Hoffman and Banerjee, 1997. “

Affiliated with

Also associated with

Rating

Influenza hemagglutinin and neuraminidase variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza hemagglutinin and neuraminidase variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza hemagglutinin and neuraminidase variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4050305